KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Total Current Liabilities (2016 - 2025)

Biomarin Pharmaceutical's Total Current Liabilities history spans 17 years, with the latest figure at $759.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 25.05% year-over-year to $759.0 million, compared with a TTM value of $759.0 million through Dec 2025, up 25.05%, and an annual FY2025 reading of $759.0 million, up 25.05% over the prior year.
  • Total Current Liabilities for Q4 2025 was $759.0 million at Biomarin Pharmaceutical, down from $798.4 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $1.2 billion in Q4 2023, with the low at $430.0 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $694.2 million, with a median of $602.6 million recorded in 2023.
  • Year-over-year, Total Current Liabilities soared 123.26% in 2023 and then crashed 48.43% in 2024.
  • Tracing BMRN's Total Current Liabilities over 5 years: stood at $546.5 million in 2021, then rose by 7.76% to $588.9 million in 2022, then skyrocketed by 99.87% to $1.2 billion in 2023, then plummeted by 48.43% to $607.0 million in 2024, then rose by 25.05% to $759.0 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Total Current Liabilities are $759.0 million (Q4 2025), $798.4 million (Q3 2025), and $684.2 million (Q2 2025).